New drug BL-M14D1 enters first human tests for tough cancers

NCT ID NCT06505824

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase study tests a new drug called BL-M14D1 in 22 adults with advanced small cell lung cancer, neuroendocrine tumors, or other solid cancers that have not responded to standard treatments. The drug is given by IV every 3 weeks. The main goals are to check safety, find the right dose, and get a first look at whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M14D1 (a drug given by IV infusion every 3 weeks)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced small cell lung cancer or neuroendocrine tumors who have run out of standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 22 participants, so the main goal is safety and dosing, not proof of effectiveness. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm neuroendocrine neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROENDOCRINE TUMORS SMALL CELL LUNG CANCER

Contacts and locations

Locations

Shanghai East Hospital
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.